Shire plc Shire Plc : Half-yearly Report -19-

Features Dow Jones Newswires

TIDMSHP

Continue Reading Below

Half-yearly Report

August 4, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), ("Shire" / the

"Group") in accordance with the Financial Conduct Authority's Disclosure

Guidance and Transparency Rules, is publishing its Half-yearly Report

for the six months ended June 30, 2017.

Continue Reading Below

On August 3, 2017, the Group announced its results for the same period.

Stephen Williams

Deputy Company Secretary

For further information please contact:

Investor Relations

Ian Karp ikarp@shire.com +1 781 482 9018

Robert Coates rcoates@shire.com +44 1256 894874

Media

Lisa Adler lisa.adler@shire.com +1 617 588 8607

Debbi Ford debbi.ford@shire.com +1 617 949 9083

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving

people with rare diseases. We strive to develop best-in-class products,

many of which are available in more than 100 countries, across core

therapeutic areas including Hematology, Immunology, Neuroscience,

Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal

Medicine / Endocrine and Hereditary Angioedema; and a growing franchise

in Oncology.

Our employees come to work every day with a shared mission: to develop

and deliver breakthrough therapies for the hundreds of millions of

people in the world affected by rare diseases and other high-need

conditions, and who lack effective therapies to live their lives to the

fullest.

www.shire.com

Shire plc

Half-yearly Report 2017

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey

JE4 8PX

Contents

The "safe harbor" statement under the Private Securities

Litigation Reform Act of 1995

Trademarks

Chief Executive Officer's review

Business overview for the six months to June 30, 2017

Results of operations for the six months to June 30,

2017 and June 30, 2016

Principal risks and uncertainties

Directors' responsibility statement

Unaudited consolidated balance sheets at June 30,

2017 and December 31, 2016

Unaudited consolidated statements of operations for

the six months to June 30, 2017 and June 30, 2016

Unaudited consolidated statements of comprehensive

income for the six months to June 30, 2017

and June 30, 2016

Unaudited consolidated statement of changes in equity

for the six months to June 30, 2017

Unaudited consolidated statement of cash flows for

the six months to June 30, 2017 and

June 30, 2016

Notes to the unaudited consolidated financial statements

Independent review report to Shire plc

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION

REFORM ACT OF 1995

Statements included herein that are not historical facts, including

without limitation statements concerning future strategy, plans,

objectives, expectations and intentions, the anticipated timing of

clinical trials and approvals for, and the commercial potential of,

inline or pipeline products, are forward-looking statements. Such

forward-looking statements involve a number of risks and uncertainties

and are subject to change at any time. In the event such risks or

uncertainties materialize, Shire's results could be materially adversely

affected. The risks and uncertainties include, but are not limited to,

the following:

-- Shire's products may not be a commercial success;

-- increased pricing pressures and limits on patient access as a result of

governmental regulations and market developments may affect Shire's

future revenues, financial condition and results of operations;

-- Shire conducts its own manufacturing operations for certain of its

products and is reliant on third party contract manufacturers to

manufacture other products and to provide goods and services. Some of

Shire's products or ingredients are only available from a single approved

source for manufacture. Any disruption to the supply chain for any of

Shire's products may result in Shire being unable to continue marketing

or developing a product or may result in Shire being unable to do so on a

commercially viable basis for some period of time;

-- the manufacture of Shire's products is subject to extensive oversight by

various regulatory agencies. Regulatory approvals or interventions

associated with changes to manufacturing sites, ingredients or

manufacturing processes could lead to, among other things, significant

delays, an increase in operating costs, lost product sales, an

interruption of research activities or the delay of new product launches;

-- certain of Shire's therapies involve lengthy and complex processes, which

may prevent Shire from timely responding to market forces and effectively

managing its production capacity;

-- Shire has a portfolio of products in various stages of research and

development. The successful development of these products is highly

uncertain and requires significant expenditures and time, and there is no

guarantee that these products will receive regulatory approval;

-- the actions of certain customers could affect Shire's ability to sell or

market products profitably. Fluctuations in buying or distribution

patterns by such customers can adversely affect Shire's revenues,

financial conditions or results of operations;

-- Shire's products and product candidates face substantial competition in

the product markets in which it operates, including competition from

generics;

-- adverse outcomes in legal matters, tax audits and other disputes,

including Shire's ability to enforce and defend patents and other

intellectual property rights required for its business, could have a

material adverse effect on the Group's revenues, financial condition or

results of operations;

-- inability to successfully compete for highly qualified personnel from

other companies and organizations;

-- failure to achieve the strategic objectives, including expected operating

efficiencies, cost savings, revenue enhancements, synergies or other

benefits at the time anticipated or at all with respect to Shire's

acquisitions, including of NPS Pharmaceuticals Inc. ("NPS"), Dyax Corp.

("Dyax") or Baxalta Incorporated ("Baxalta"), may adversely affect

Shire's financial condition and results of operations;

-- Shire's growth strategy depends in part upon its ability to expand its

product portfolio through external collaborations, which, if unsuccessful,

may adversely affect the development and sale of its products;

-- a slowdown of global economic growth, or economic instability of

countries in which Shire does business, as well as changes in foreign

currency exchange rates and interest rates, that adversely impact the

availability and cost of credit and customer purchasing and payment

patterns, including the collectability of customer accounts receivable;

-- failure of a marketed product to work effectively or if such a product is

the cause of adverse side effects could result in damage to Shire's

reputation, the withdrawal of the product and legal action against Shire;

-- investigations or enforcement action by regulatory authorities or law

enforcement agencies relating to Shire's activities in the highly

regulated markets in which it operates may result in significant legal

costs and the payment of substantial compensation or fines;

-- Shire is dependent on information technology and its systems and

infrastructure face certain risks, including from service disruptions,

the loss of sensitive or confidential information, cyber-attacks and

other security breaches or data leakages that could have a material

adverse effect on Shire's revenues, financial condition or results of

operations;

-- Shire incurred substantial additional indebtedness to finance the Baxalta

acquisition, which has increased its borrowing costs and may decrease its

business flexibility; and

a further list and description of risks, uncertainties and other matters

can be found in Shire's most recent Annual Report on Form 10-K and in

Shire's subsequent Quarterly Reports on Form 10-Q, in each case

including those risks outlined in "ITEM 1A: Risk Factors", and in

subsequent reports on Form 8-K and other Securities and Exchange

Commission filings, all of which are available on Shire's website.

All forward-looking statements attributable to the Group or any person

acting on its behalf are expressly qualified in their entirety by this

cautionary statement. Readers are cautioned not to place undue reliance

on these forward-looking statements that speak only as of the date

hereof. Except to the extent otherwise required by applicable law, the

Group does not undertake any obligation to update or revise

forward-looking statements, whether as a result of new information,

future events or otherwise.

Trademarks

The Group owns or has rights to trademarks, service marks or trade names

that are used in connection with the operation of its business. In

addition, its names, logos and website names and addresses are owned by

the Group or licensed by the Group. The Group also owns or has the

rights to copyrights that protect the content of its solutions. Solely

for convenience, the trademarks, service marks, trade names and

copyrights referred to in this Quarterly Report on Form 10-Q are listed

without the (c), (R) and (TM) symbols, but the Group will assert, to the

fullest extent under applicable law, its rights or the rights of the

applicable licensors to these trademarks, service marks, trade names and

copyrights.

This Half-yearly Report may include trademarks, service marks or trade

names of other companies. The Group's use or display of other parties'

trademarks, service marks, trade names or products is not intended to,

and does not imply a relationship with, or endorsement or sponsorship of

the Group by, the trademark, service mark or trade name.

Chief Executive Officer's review

We are pleased to enclose our financial results for the six-month period

ended June 30, 2017. This Half-yearly Report includes condensed

consolidated financial statements prepared in accordance with generally

accepted accounting principles in the United States of America ("U.S.

GAAP").

Flemming Ornskov, M.D., M.P.H. Shire's Chief Executive Officer,

commented:

"Shire delivered strong top-line growth and significantly advanced our

pipeline during the first half of 2017. We saw significant contributions

from our broad and diverse portfolio and further realized cost synergies

from our integration with Baxalta, which continued ahead of schedule.

"Total reported product sales in the first half of 2017 were $7.0

billion, up 77% against first half of 2016, primarily due to the

inclusion of Baxalta product revenues. We also delivered product sales

growth in Shire's legacy business versus first half of 2016: Genetic

Diseases up 8% to $1,401 million and Internal Medicine up 12% to $903

million.

"We continued to drive the late-stage clinical pipeline, with milestones

achieved in programs across our core therapeutic areas. Most recently,

we announced positive topline data from our Phase 3 pivotal trial of

SHP643 in Hereditary Angioedema, and anticipate submission of the BLA in

late 2017 or early 2018. MYDAYIS, a once-daily treatment for patients

with ADHD, received US FDA approval and will be launched in September.

In addition, we were granted European Union (EU) Conditional Marketing

Authorisation for NATPAR (Parathyroid Hormone) for the treatment of

patients with chronic hypoparathyroidism, and received European

Medicines Agency (EMA) validation of the VEYVONDI [von Willebrand factor

(Recombinant)] Marketing Authorization Application for treatment of von

Willebrand Disease (VWD).

"We are at an exciting inflection point, with both our rare disease and

neuroscience businesses performing strongly and each having significant

growth potential over the coming years. The strength and scale of our

business provides us with the opportunity to further optimize our

franchise portfolio - one of our key priorities communicated earlier

this year. By year end, we expect to complete a formal evaluation of the

full range of strategic options for the neuroscience franchise,

including the potential for its independent public listing.

"As we enter the second half of 2017, we are focused on generating

strong organic growth while continuing to deliver on our key priorities

- launching more than 80 products globally by leveraging our expanded

commercial platform, progressing our late-stage pipeline, integrating

Baxalta, and paying down debt. We remain very confident about Shire's

long-term prospects."

Flemming Ornskov, M.D., M.P.H.

Chief Executive Officer

Business overview for the six months to June 30, 2017

The following discussion should be read in conjunction with the

unaudited condensed consolidated financial statements and related notes

appearing elsewhere in this Half-yearly Report.

Significant Events in the Six Months Ended June 30, 2017 and Recent

Developments

Corporate Strategy

Shire to assess strategic options for its Neuroscience franchise

-- As part of the Board's ongoing commitment to optimize Shire's portfolio

and strategic focus, Shire is assessing strategic options for our

Neuroscience franchise. These options may include the independent public

listing of the Neuroscience franchise. Shire intends to complete this

strategic review by year end.

Business Development

Shire entered into a licensing agreement for SHP659 (formerly known as

P-321)

-- On May 1, 2017, Shire announced it agreed to license the exclusive

worldwide rights to P-321 from Parion Sciences. P-321 is a Phase 2

investigational epithelial sodium channel inhibitor for the potential

treatment of dry eye disease in adults. Shire will develop, and if

approved, commercialize this compound which would expand our leadership

position in ophthalmics and provide another important treatment option

for patients with dry eye disease.

Shire entered into a licensing agreement for Novimmune bi-specific

antibody

-- On July 18, 2017, Shire entered into a licensing agreement with Novimmune

S.A. The license grants Shire exclusive worldwide rights to develop and

commercialize a bi-specific antibody in pre-clinical development for the

treatment of hemophilia A and hemophilia A patients with inhibitors.

Products

FIRAZYR for the treatment of Hereditary Angioedema ("HAE") in Japan

-- On July 6, 2017, Shire submitted a Japanese New Drug Application to the

Pharmaceutical and Medical Devices Agency in Japan for the treatment of

HAE.

VEYVONDI for the treatment of adults affected by Von Willebrand Disease

("VWD")

-- On June 22, 2017, Shire announced that the European Medicines Agency

("EMA") validated the Marketing Authorization Application for VEYVONDI to

prevent and treat bleeding episodes and peri-operative bleeding in adults

(age 18 and older) diagnosed with VWD.

MYDAYIS for the treatment of attention deficit hyperactivity disorder

("ADHD")

-- On June 20, 2017, Shire announced that the U.S. Food and Drug

Administration ("FDA") approved MYDAYIS (mixed salts of a single-entity

amphetamine product), a once-daily treatment comprised of three different

types of drug-releasing beads for patients aged 13 years and older with

ADHD.

NATPAR for the treatment of chronic hypoparathyroidism

-- On April 26, 2017, Shire announced the European Commission (EC) granted

Conditional Marketing Authorization for NATPAR (rhPTH[1-84]), the first

recombinant human protein with the full length 84-aminoacid sequence of

endogenous parathyroid hormone (PTH), as an adjunctive treatment for

adult patients with chronic hypoparathyroidism who cannot be adequately

controlled with standard therapy alone.

VYVANSE for the treatment of ADHD and Binge Eating Disorder ("BED")

-- On April 18, 2017, Shire announced that VYVANSE (lisdexamfetamine

dimesylate) CII is now available in the United States in a new chewable

tablet formulation, following FDA approval in January 2017.

INTUNIV for the treatment of ADHD in Japan

-- On March 30, 2017, Shire's partner in Japan, Shionogi & Co., Ltd,

received approval from the Japanese Ministry of Health, Labor and Welfare

to manufacture and market INTUNIV for ADHD in Japan.

-- On May 29, 2017, Shire's partner in Japan, Shionogi & Co., Ltd, launched

INTUNIV for the treatment of ADHD in children and adolescents from six to

17 years old.

CINRYZE for the treatment of HAE

-- On March 16, 2017, the EC approved a label extension for CINRYZE (C1

inhibitor [human]), broadening its use to children with HAE. CINRYZE is

now the first and only treatment indicated for routine prevention of

angioedema attacks in children aged six years or older who have severe

and recurrent attacks of HAE and cannot tolerate or are not adequately

protected by oral preventative treatments, or who are inadequately

managed with repeated acute treatment. CINRYZE is also now approved for

acute treatment and pre-procedure prevention of angioedema attacks in

children aged two years or older with HAE.

Pipeline

SHP654 for the treatment of hemophilia A

-- On July 6, 2017, Shire announced the submission of an Investigational New

Drug ("IND") application to the FDA for SHP654, an investigational factor

VIII (FVIII) gene therapy for the treatment of hemophilia A.

SHP643 for the treatment of HAE

-- On May 18, 2017, Shire announced positive topline Phase 3 results for the

HELP Study, which evaluated the efficacy and safety of subcutaneously

administered lanadelumab in patients 12 years of age or older with HAE.

The study met its primary endpoint and all secondary endpoints.

SHP647 for the treatment of ulcerative colitis

-- On May 17, 2017, Shire announced the publication of positive Phase 2

results for the TURANDOT Study. The study met its primary endpoint,

demonstrating significantly greater remission rates in patients receiving

the anti-MAdCAM antibody. Shire continues to work towards the initiation

of a pivotal Phase 3 trial for SHP647 in the second half of 2017.

SHP680 for the treatment of multiple neurological conditions

-- Shire is advancing clinical development of SHP680 targetting indications

for multiple neurological conditions with high unmet need. SHP680 is a

new chemical entity prodrug of d-amphetamine, which has previously been

studied in Phase 1 clinical trials, demonstrating a unique PK profile. It

belongs to a class of molecules with an established and well understood

safety profile.

SHP655 for the treatment of congenital thrombotic thrombocytopenic

purpura (cTTP)

-- On March 22, 2017, the FDA granted Fast Track Designation for recombinant

ADAMTS13 (SHP655) for the treatment of acute episodes of cTTP in patients

with a congenital deficiency of the von Willebrand factorcleaving

protease ADAMTS13.

SHP640 for the treatment of bacterial and adenoviral conjunctivitis

-- The global Phase 3 clinical development program will have clinical sites

in over 20 countries. Patient recruitment has started and the first

patient visit occurred in March 2017. The topline data is expected in Q2

2018.

SHP639 for the treatment of Glaucoma

-- In March 2017, Shire submitted an (IND) application for SHP639. The IND

is for the initiation of first in human clinical studies of SHP639 for

the reduction of elevated intraocular pressure in patients with primary

open-angle glaucoma or ocular hypertension.

Board Changes

In accordance with Shire's normal succession planning, the Group

announced that the following Non-Executive Directors will retire from

the Board with effect from the conclusion of the 2018 Annual General

Meeting ("AGM"):

-- William M. Burns, Senior Independent Director

-- David Ginsburg, Chairman of the Science & Technology Committee

-- Anne Minto, Chairman of the Remuneration Committee

Al Stroucken, Non-Executive Director, assumed the position of Chairman

of the Remuneration Committee effective August 3, 2017. Anne Minto will

continue to serve as a member of the Remuneration Committee to enable a

period of transition until her retirement from the Board. Anne will

fully support Al in the shareholder consultation process ahead of the

publication of the new Directors' Remuneration Policy that will be put

forward for shareholder approval at the 2018 AGM. The Board, supported

by the Nomination & Governance Committee, will continue to evaluate

Board and committee membership, including succession plans for the roles

of Senior Independent Director and Chairman of the Science & Technology

Committee, and will announce further changes once finalized.

Dividend

In respect of the six months ended June 30, 2017, the Board resolved to

pay an interim dividend of 0.0509 U.S. dollars per ordinary share (2016:

0.0463 U.S. dollars per ordinary share).

Dividend payments will be made in Pounds sterling to holders of ordinary

shares and in U.S. dollars to holders of ADSs. A dividend of 0.0385 (1)

Pounds sterling per ordinary share (2016: 0.0351 Pounds sterling) and

0.1527 U.S. dollars per ADS (2016: 0.1389 U.S. dollars) will be paid on

October 20, 2017, to shareholders on the register as of the close of

business on September 8, 2017.

Holders of ordinary shares are notified that, in order to receive UK

sourced dividends via Shire's Income Access Share arrangements ("IAS

Arrangements"), they need to have submitted a valid IAS Arrangements

election form to the Group's Registrar, Equiniti, by no later than 5pm

(BST) on September 22, 2017. Holders of ordinary shares are advised

that:

-- any previous elections made using versions of the IAS Arrangements

election form in use prior to February 16, 2016, and any elections deemed

to have been made prior to April 28, 2016, are no longer valid; and

-- if they do not elect, or have not elected using the newly formatted IAS

Arrangements election forms published on or after February 16, 2016, to

receive UK sourced dividends via Shire's IAS Arrangements, their

dividends will be Irish sourced and therefore incur Irish dividend

withholding tax, subject to applicable exemptions.

Internet links to the newly formatted IAS Arrangements election forms

can be found at:

http://investors.shire.com/shareholder-information/shareholder-forms.aspx

(1) Translated using a GBP:USD exchange rate of 1.3221.

Going Concern

As stated in Note 1 to the unaudited consolidated financial statements,

the Directors have a reasonable expectation that the Group has adequate

resources to continue in operational existence for the foreseeable

future. Accordingly, the Directors consider it appropriate to adopt the

going concern basis of accounting in preparing the Half-yearly Report.

Results of Operations for the Three and Six Months Ended June 30, 2017

and 2016

Product sales

The following table provides an analysis of the Group's Product sales:

(In millions,

except %) Three months ended June 30, Six months ended June 30,

Product Product

sales sales

Product sales: 2017 2016 growth 2017 2016 growth

HEMOPHILIA $ 743.9 $ 275.6 N/M $1,394.3 $ 275.6 N/M

INHIBITOR

THERAPIES 220.7 74.0 N/M 441.2 74.0 N/M

Hematology total 964.6 349.6 N/M 1,835.5 349.6 N/M

CINRYZE 175.9 173.0 2% 401.8 337.2 19%

ELAPRASE 161.0 154.0 5% 301.6 277.6 9%

FIRAZYR 137.4 136.7 1% 265.9 265.0 -%

REPLAGAL 122.1 118.4 3% 231.8 221.6 5%

VPRIV 87.9 88.0 -% 167.7 171.6 (2)%

KALBITOR 20.6 17.7 16% 32.3 28.1 15%

Genetic Diseases

total 704.9 687.8 2% 1,401.1 1,301.1 8%

IMMUNOGLOBULIN

THERAPIES 510.5 138.2 N/M 1,008.8 138.2 N/M

BIO THERAPEUTICS 172.2 51.3 N/M 350.1 51.3 N/M

Immunology total 682.7 189.5 N/M 1,358.9 189.5 N/M

VYVANSE 518.2 517.7 -% 1,081.9 1,026.9 5%

ADDERALL XR 71.4 101.8 (30)% 136.3 200.6 (32)%

MYDAYIS 15.7 - N/A 15.7 - N/A

Other

Neuroscience 30.1 35.7 (16)% 54.8 57.8 (5)%

Neuroscience

total 635.4 655.2 (3)% 1,288.7 1,285.3 -%

LIALDA/MEZAVANT 207.8 193.7 7% 382.9 361.7 6%

PENTASA 83.3 72.9 14% 152.4 136.9 11%

GATTEX/REVESTIVE 75.3 44.5 69% 144.3 96.2 50%

NATPARA 34.5 19.9 73% 64.2 35.5 81%

Other Internal

Medicine 83.4 88.7 (6)% 159.3 173.3 (8)%

Internal Medicine

total 484.3 419.7 15% 903.1 803.6 12%

Oncology total 62.5 20.3 N/M 120.8 20.3 N/M

Ophthalmology

total 57.4 - N/A 96.0 - N/A

Total Product

sales $3,591.8 $2,322.1 55% $7,004.1 $3,949.4 77%

N/M: Baxalta sales have only been included in the consolidated results

of the Group since the date of acquisition; therefore, Product sales

growth as a percentage is not meaningful.

Hematology

Hematology was acquired with Baxalta in June 2016 and includes sales of

recombinant and plasma-derived hemophilia products (primarily factor

VIII and factor IX) and inhibitor therapies. Hematology product sales,

totaling $964.6 million and $1,835.5 million, respectively, are included

in Product sales for the three and six months ended June 30, 2017,

representing 27% and 26% of Shire's reported Product sales,

respectively.

Genetic Diseases

Genetic Diseases product sales for the three and six months ended June

30, 2017 increased by 2% and 8%, respectively, compared to the

corresponding periods in 2016. Growth was primarily driven by the

Group's lysosomal storage diseases portfolio and CINRYZE.

ELAPRASE product sales for the three and six months ended June 30, 2017

increased by 5% and 9%, respectively, while REPLAGAL sales increased by

3% and 5%, respectively, compared to the corresponding periods in 2016.

Both products benefited from an increase in the number of patients on

therapy.

CINRYZE product sales for the three and six months ended June 30, 2017

increased by 2% and 19%, respectively. The growth in the three months

ended June 30, 2017 was primarily due to an increase in number of

patients, partially offset by destocking during the second quarter of

2017. The growth in the six months ended June 30, 2017 was primarily due

to an increase in number of patients and the impact of U.S. stocking in

the first half of 2017.

Immunology

Immunology was acquired with Baxalta in June 2016 and includes product

sales of antibody-replacement immunoglobulin and bio therapeutics

therapies. Immunology product sales, totaling $682.7 million and

$1,358.9 million, respectively, are included in Product sales for the

three and six months ended June 30, 2017, representing 19% of Shire's

reported Product sales, in each respective period.

Neuroscience

Neuroscience product sales for the three months ended June 30, 2017

decreased by 3% compared to the corresponding period in 2016, primarily

driven by ADDERALL XR. Product sales for the six months ended June 30,

2017 increased less than 1% compared to the corresponding period in

2016.

ADDERALL XR sales decreased by 30% and 32%, respectively, during the

three and six months ended June 30, 2017 compared to the corresponding

periods in 2016, primarily due to additional generic competition since

August 2016.

VYVANSE product sales increased by less than 1% and 5% for the three and

six months ended June 30, 2017, respectively, compared with the

corresponding periods in 2016. The three months ended June 30, 2017

growth was impacted by destocking in the second quarter of 2017 compared

to stocking in the corresponding period in 2016. During the six months

ended June 30, 2017, VYVANSE sales increased due to year-over-year

prescription growth in the U.S., the benefit of a price increase taken

since the first quarter of 2016 and growth in international markets,

partially offset by destocking.

MYDAYIS, approved by the FDA on June 20, 2017, contributed $15.7 million

of product sales related to launch stocking.

Internal Medicine

Internal Medicine product sales increased by 15% and 12%, respectively,

during the three and six months ended June 30, 2017, compared to the

corresponding periods in 2016, with growth primarily driven by

GATTEX/REVESTIVE and NATPARA.

GATTEX/REVESTIVE and NATPARA reported increased product sales of 69% and

73% during the three months ended June 30, 2017 and 50% and 81% during

the six months ended June 30, 2017, respectively, primarily due to an

increase in the numbers of patients on therapy.

During the second quarter of 2017, a generic version of LIALDA was

approved by the FDA; Shire expects generic competition to negatively

impact future LIALDA product sales.

Oncology

Oncology was acquired with Baxalta in June 2016 and includes sales of

ONCASPAR and ONIVYDE, the latter of which was approved in the EU on

October 18, 2016. Oncology product sales, totaling reported sales of

$62.5 million and $120.8 million respectively, are included in Product

sales for the three and six months ended June 30, 2017, representing 2%

Shire's reported Product sales, in each respective period.

Ophthalmology

Ophthalmology product sales relate to XIIDRA, which was made available

to patients starting on August 29, 2016. XIIDRA contributed $57.4

million and $96.0 million of product sales during the three and six

months ended June 30, 2017.

Royalties and other revenues

The following table provides an analysis of Shire's income from

royalties and other revenues:

Three months ended June

30, Six months ended June 30,

(In millions,

except %) 2017 2016 Change % 2017 2016 Change %

SENSIPAR

Royalties $ 46.4 $ 35.6 30% $ 85.3 $ 73.5 16%

ADDERALL XR

Royalties 13.4 5.2 158% 25.9 11.0 135%

FOSRENOL

Royalties 12.1 11.4 6% 20.7 20.6 -%

3TC and ZEFFIX

Royalties 8.2 12.1 (32)% 22.7 27.1 (16)%

Other

Royalties and

Revenues 73.9 42.7 73% 159.4 56.8 181%

Total

Royalties and

other

revenues $154.0 $107.0 44% $314.0 $189.0 66%

Royalties and other revenues increased 44% and 66%, respectively, during

the three and six months ended June 30, 2017 compared to the

corresponding periods in 2016, primarily due to the inclusion of

contract manufacturing revenue acquired with Baxalta.

Cost of sales

Cost of sales as a percentage of Total revenues decreased to 30% for the

three months ended June 30, 2017, compared to 32% for the corresponding

period in 2016, primarily due to lower expense related to the unwind of

inventory fair value adjustments. Cost of sales as a percentage of Total

revenues increased to 33% for the six months ended June 30, 2017,

compared to 25% in the corresponding period in 2016, primarily due to

the impact of the unwind of inventory fair value adjustments and

increased depreciation following the acquisition of Baxalta on June 3,

2016.

For the three and six months ended June 30, 2017, Cost of sales included

depreciation of $67.0 million and $139.1 million, respectively (2016:

$22.4 million and $30.7 million, respectively).

Research and development

In the three and six months ended June 30, 2017, Research and

development expenses increased by $247.6 million and $409.8 million, or

84% and 80%, respectively, compared to the corresponding periods in

2016, primarily due to milestone and upfront payments associated with

license arrangements and the inclusion of Baxalta costs.

For the three and six months ended June 30, 2017, Research and

development included depreciation of $12.8 million and $26.2 million,

respectively (2016: $5.8 million and $11.7 million, respectively).

Selling, general and administrative

In the three and six months ended June 30, 2017, Selling, general and

administrative expenses increased by $223.8 million and $637.8 million,

or 33% and 55%, compared to the corresponding periods in 2016, primarily

due to the inclusion of Baxalta related costs and increased XIIDRA

marketing costs.

For the three and six months ended June 30, 2017, Selling, general and

administrative expenses included depreciation of $40.9 million and $78.3

million, respectively (2016: $19.7 million and $39.8 million,

respectively).

Amortization of acquired intangible assets

For the three and six months ended June 30, 2017, Shire recorded

Amortization of acquired intangible assets of $434.1 million and $798.1

million, respectively, compared to $213.0 million and $347.6 million,

respectively, in the corresponding periods in 2016. The increase is

primarily related to amortization on the intangible assets acquired with

the acquisition of Baxalta.

Integration and acquisition costs

In the three and six months ended June 30, 2017, Shire recorded

Integration and acquisition costs of $343.7 million and $459.7 million,

respectively, compared to $363.0 million and $454.1 million,

respectively, in the corresponding periods in 2016.

In 2017, Integration and acquisition costs included a net charge of

$151.2 million, primarily relating to the change in fair value of

contingent consideration for SHP643, which was acquired from Dyax in

2016. The Baxalta integration and acquisition costs include $80.2

million and $117.1 million, respectively, of employee severance and

acceleration of stock compensation, $50.4 million and $85.6 million,

respectively, of third-party professional fees and $17.2 million and

$41.7 million, respectively, of expenses associated with facility

consolidations for the three and six months ended June 30, 2017. The

Group also recognized $33.6 million of expenses during the three and six

months ended June 30, 2017 related to asset impairments.

For the three and six months ended June 30, 2016, Integration and

acquisition costs primarily consist of $67.1 million and $125.6 million,

respectively, of acquisition costs including legal, investment banking

and other transaction-related fees, $254.5 million and $265.5 million,

respectively, of employee severance and acceleration of stock

compensation, $79.2 million and $89.2 million, respectively, of

third-party professional fees and $56.5 million and $45.1 million,

respectively, of change in fair value of contingent consideration.

Interest expense

For the three and six months ended June 30, 2017, Shire incurred

Interest expense of $141.3 million and $283.6 million, respectively,

primarily due to higher interest expense incurred on borrowings used to

fund the acquisitions of Dyax and Baxalta.

For the three and six months ended June 30, 2016, Shire incurred

Interest expense of $87.2 million and $131.9 million, respectively,

primarily related to the interest and amortization of financing fees

incurred on borrowings to fund the acquisition of Dyax and the

amortization of one-time upfront arrangement fees incurred on borrowings

associated with the acquisition of Baxalta.

Taxation

The effective tax rate on income from continuing operations for the

three and six months ended June 30, 2017 was 9% and 5% (2016: -427% and

2%), respectively.

The effective tax rate for the three and six months ended June 30, 2017

and 2016 was driven by the combined impact of the relative quantum of

profit before tax for the period by jurisdiction as well as acquisition

and integration costs in higher tax territories.

Discontinued Operations

The loss from discontinued operations for the three months ended June

30, 2017 was $1.2 million, net of taxes, and the gain for the six months

ended June 30, 2017 was $19.0 million, net of taxes. The loss during the

three months ended June 30, 2017 was primarily related to the divested

DERMAGRAFT business and the gain during the six months ended June 30,

2017 was primarily due to the return of funds previously held in escrow

related to the acquisition of the DERMAGRAFT business.

The loss from discontinued operations for the three and six months ended

June 30, 2016 was $248.7 million and $239.2 million, respectively, net

of taxes, primarily related to the establishment of legal contingencies

related to the divested DERMAGRAFT business.

Financial condition at June 30, 2017 and December 31, 2016

Cash and cash equivalents:

Cash and cash equivalents decreased by $265.1 million to $263.7 million

at June 30, 2017 (December 31, 2016: $528.8 million). The net decrease

was primarily related to $1,681.9 million of net cash provided by

operating activities, which was partially offset by net repayments of

debt ($1,416.0 million), purchases of fixed assets ($391.1 million), and

payment of dividends ($234.7 million).

Accounts receivable, net:

Accounts receivable, net increased by $138.7 million to $2,755.2 million

at June 30, 2017 (December 31, 2016: $2,616.5 million) due to higher

revenue, in part related to our newly launched product, MYDAYIS.

Inventories

Inventories decreased by $237.0 million to $3,325.3 million at June 30,

2017 (December 31, 2016: $3,562.3 million) primarily due to the

amortization of the unwind of inventory fair value adjustments ($625.4

million), offset by increases in inventory levels to support higher

demand of immunology and hematology products and expected demand for our

ophthalmology product.

Goodwill

Goodwill increased by $1,593.9 million to $19,482.1 million at June 30,

2017 (December 31, 2016: $17,888.2 million), principally due to

finalizing the purchase accounting related to the Baxalta acquisition.

Intangible assets, net

Intangible assets, net decreased by $1,263.2 million to $33,434.3

million at June 30, 2017 (December 31, 2016: $34,697.5 million),

principally due to finalizing the purchase accounting related to the

Baxalta acquisition. As of June 30, 2017, we completed our purchase

accounting. We had previously disclosed that the fair values of those

assets were preliminary and subject to change pending the completion of

our valuation work.

Accounts payable and accrued expenses

Accounts payable and accrued expenses decreased by $470.4 million to

$3,842.0 at June 30, 2017 (December 31, 2016: $4,312.4 million)

primarily related to the settlement of legal contingencies

(approximately $350 million) related to the divested Dermagraft

business.

Short and long term borrowings and capital leases

Short and long term borrowings and capital leases decreased by a net of

$1,407.8 million to $21,560.0 million at June 30, 2017 (December 31,

2016: $22,967.8 million) primarily related to the repayments of senior

notes and other long term debt ($1,701.0 million), partially offset by

an increase in short term borrowings under the revolving credit facility

($285.0 million).

Non-current deferred tax liabilities

Non-current deferred tax liabilities decreased by $534.7 million to

$7,788.0 million at June 30 2017 (December 31, 2016: $8,322.7 million)

primarily due to adjustments for the deferred tax liabilities arising on

intangible assets acquired with Baxalta. As of June 30, 2017 we

completed our purchase accounting related to the Baxalta transaction.

Other non-current liabilities

Other non-current liabilities increased by $224.6 million to $2,346.2

million at June 30, 2017 (December 31, 2016: $2,121.6 million)

principally due the increase in the fair value of contingent

consideration payable primarily associated with the SHP643 (lanadelumab)

IPR&D intangible asset acquired with the Dyax transaction, an increase

in income tax payable as well as an increase in pension liability.

Liquidity and Capital Resources

General

The Group's funding requirements depend on a number of factors,

including the timing and extent of its development programs; corporate,

business and product acquisitions; the level of resources required for

the expansion of certain manufacturing and marketing capabilities as the

product base expands; increases in accounts receivable and inventory

which may arise with any increase in product sales; technological

developments; the timing and cost of obtaining required regulatory

approvals for new products; the timing and quantum of milestone payments

on business combinations, in-licenses and collaborative projects; the

timing and quantum of tax and dividend payments; the timing and quantum

of purchases by the Employee Benefit Trust of Shire shares in the market

to satisfy awards granted under Shire's employee share plans and the

amount of cash generated from sales of Shire's products and royalty

receipts.

An important part of Shire's business strategy is to protect its

products and technologies through the use of patents, proprietary

technologies and trademarks, to the extent available. The Group intends

to defend its intellectual property and as a result may need cash for

funding the cost of litigation.

The Group finances its activities through cash generated from operating

activities, credit facilities, private and public offerings of equity

and debt securities and the proceeds of asset or investment disposals.

Shire's Consolidated Balance Sheets include $263.7 million of Cash and

cash equivalents as of June 30, 2017.

Shire has a revolving credit facility ("RCF") of $2,100.0 million, which

matures in 2021, $735.0 million of which was utilized as of June 30,

2017. The RCF incorporates a $250.0 million U.S. dollar and Euro

swingline facility operating as a sub-limit thereof.

In connection with the acquisition of Dyax, Shire entered into a $5.6

billion amortizing term loan facility in November 2015. As of June 30,

2017, $3.3 billion of this term loan facility was outstanding. The

facility matures in different tranches through November 2018 and $1.7

billion is due within the next twelve months.

In connection with the acquisition of Baxalta, Shire assumed $5.0

billion of unsecured senior notes previously issued by Baxalta, of which

$750.0 million is due within the next twelve months and issued $12.1

billion of unsecured senior notes in September 2016, of which none are

due for repayment in the next twelve months.

The details of these financing arrangements are included in Note 13,

Borrowings and Capital Leases, to these Unaudited Consolidated Financial

Statements.

In addition, Shire also has access to certain short-term uncommitted

lines of credit which are available to utilize from time to time to

provide short-term cash management flexibility. As of June 30, 2017,

these lines of credit were not utilized.

The Group may also engage in financing activities from time to time,

including accessing the debt or equity capital markets.

Financing

Shire anticipates that its operating cash flow together with available

cash, cash equivalents, and the RCF will be sufficient to meet its

anticipated future operating expenses, capital expenditures, tax and

interest payments, lease obligations, repayment of borrowings and

milestone payments as they become due over the next twelve months.

If the Group decides to acquire other businesses, it expects to fund

these acquisitions from cash resources, the RCF and through new

borrowings (including issuances of debt securities) or the issuance of

new equity, if necessary.

Sources and uses of cash

The following table provides an analysis of the Group's gross and net

debt position (excluding restricted cash), as of June 30, 2017 and

December 31, 2016:

(In millions) June 30, 2017 December 31, 2016

Cash and cash equivalents $ 263.7 $ 528.8

Long term borrowings (excluding

capital leases) (18,011.3) (19,552.6)

Short term borrowings (excluding

capital leases) (3,198.1) (3,061.6)

Capital leases (350.6) (353.6)

Total debt $ (21,560.0) $ (22,967.8)

Net debt $ (21,296.3) $ (22,439.0)

-- Net debt is a Non-GAAP measure. Net debt represents U.S. GAAP Cash and

cash equivalents less U.S. GAAP short and long term borrowings and

capital leases (see above). The Group believes that Net debt is a useful

measure as it indicates the level of borrowings after taking account of

the Cash and cash equivalents that could be utilized to pay down the

outstanding borrowings.

-- Substantially all of the Group's Cash and cash equivalents are held by

foreign subsidiaries (i.e., those subsidiaries incorporated outside of

Jersey, Channel Islands, the jurisdiction of incorporation of Shire plc,

Shire's holding company). The amount of Cash and cash equivalents held by

foreign subsidiaries has not had, and is not expected to have, a material

impact on the Group's liquidity and capital resources.

Cash flow activity

Net cash provided by operating activities increased by $701.5 million,

or 72%, to $1,681.9 million (2016: $980.4 million) during the six months

ended June 30, 2017, primarily due to increased cash receipts from

higher sales, partially offset by a payment of $351.6 million associated

with the settlement of the DERMAGRAFT litigation.

Net cash used in investing activities was $355.9 million during the six

months ended June 30, 2017, principally relating to cash paid for

purchases of PP&E and long term investments.

Net cash used in financing activities was $1,595.2 million during the

six months ended June 30, 2017. This includes $1,700.0 million of

scheduled and advance repayments under the November 2015 Facility B and

a dividend payment of $234.7, which was partially offset by $285.0

million of increased borrowings under the RCF and $79.5 million of cash

proceeds from the exercise of options.

Obligations and commitments

There were no material changes to the Group's contractual obligations

previously disclosed in Review of our Business in Shire's Annual Report

and Accounts for the year ended December 31, 2016.

Recent Accounting Pronouncements

A description of recently issued accounting standards is included under

the heading "New Accounting Pronouncements" in Note 1, Summary of

Significant Accounting Policies.

Principal risks and uncertainties

The Group's risk management strategy is to identify, assess and mitigate

any significant risks that it faces. Despite this, it should be noted

that no risk management strategy can provide absolute assurance against

loss.

The Group's processes for managing these risks are consistent with those

outlined in Shire's Annual Report and Accounts for the year ended

December 31, 2016, which is available on the Group's website,

www.shire.com.

The principal risks and uncertainties affecting the Group for the

remaining six months of 2017 are those described under the headings

below. It is not anticipated that the nature of the principal risks and

uncertainties disclosed in full in Shire's Annual Report and Accounts

for the year ended December 31, 2016, will change in respect of the

second half of 2017. The Group believes that these risk factors apply

equally and therefore all should be carefully considered before any

investment is made in Shire.

Shire's combination with Baxalta closed on June 3, 2016. All references

to the "Group," "Shire," "we," "us," or "our" used herein refer to Shire

plc and its subsidiaries, including Baxalta and its subsidiaries.

In summary, these risks and uncertainties are as follows:

Risks Related to Our Business

-- The Group's products may not be a commercial success.

-- Increased pricing pressures and limits on patient access as a result of

governmental regulations and market developments may affect the Group's

future revenues, financial condition and results of operations.

-- The Group depends on third-parties to supply certain inputs and services

critical to its operations including certain inputs, services and

ingredients critical to its manufacturing processes.

-- Any disruption to the supply chain for any of the Group's products, or

any difficulties or delays in the manufacturing, distribution and sale of

its products may result in the Group being unable to continue marketing

or developing a product, or may result in the Group being unable to do so

on a commercially viable basis for some period of time.

-- The manufacture of the Group's products is subject to extensive oversight

by various regulatory agencies. Regulatory approvals or interventions

associated with changes to manufacturing sites, ingredients or

manufacturing processes could lead to significant delays, an increase in

operating costs, lost product sales, an interruption of research

activities or the delay of new product launches.

-- The nature of producing plasma-based therapies may prevent Shire from

timely responding to market forces and effectively managing its

production capacity.

-- The Group has a portfolio of products in various stages of research and

development. The successful development of these products is

highly uncertain and requires significant expenditures and time, and

there is no guarantee that these products will receive regulatory

approval.

-- The actions of certain customers could affect the Group's ability to sell

or market products profitably. Fluctuations in buying or distribution

patterns by such customers can adversely affect the Group's revenues,

financial conditions or results of operations.

-- Failure to comply with laws and regulations governing the sales and

marketing of its products could materially impact Shire's revenues and

profitability.

-- The Group's products and product candidates face substantial

competition in the product markets in which it operates.

-- The Group's patented products are subject to significant competition from

generics.

-- Adverse outcomes in legal matters and other disputes, including the

Group's ability to enforce and defend patents and other intellectual

property rights required for its business, could have a material adverse

effect on the Group's revenues, financial condition or results of

operations.

-- The Group may fail to obtain, maintain, enforce or defend the

intellectual property rights required to conduct its business.

-- The Group faces intense competition for highly qualified personnel from

other companies and organizations.

-- Failure to successfully execute or attain strategic objectives from the

Group's acquisitions and growth strategy may adversely affect the Group's

financial condition and results of operations.

-- Shire's growth strategy depends in part upon its ability to expand its

product portfolio through external collaborations, which, if unsuccessful,

may adversely affect the development and sale of its products.

-- A slowdown of global economic growth, or economic instability of

countries in which the Group does business, could have negative

consequences for the Group's business and increase the risk of

non-payment by the Group's customers.

-- Changes in foreign currency exchange rates and interest rates could have

a material adverse effect on Shire's operating results and liquidity.

-- The Group is subject to evolving and complex tax laws, which may result

in additional liabilities that may adversely affect the Group's financial

condition or results of operations.

-- If a marketed product fails to work effectively or causes adverse side

effects, this could result in damage to the Group's reputation, the

withdrawal of the product and legal action against the Group.

-- The Group is dependent on information technology and its systems and

infrastructure face certain risks, including from service disruptions,

the loss of sensitive or confidential information, cyber-attacks and

other security breaches or data leakages that could have a material

adverse effect on the Group's revenues, financial condition or results of

operations.

-- Shire faces risks relating to the expected exit of the United Kingdom

from the European Union.

Risks Related to the Combination with Baxalta Incorporated

-- The Group may not successfully integrate the businesses of Shire

and Baxalta.

-- Shire has incurred significant additional indebtedness in connection with

the acquisition, which has decreased the Group's business flexibility and

increased its interest expense. All of the Group's debt obligations have

priority over the Group's Ordinary Shares and ADSs with respect to

payment in the event of a liquidation, dissolution or winding up.

-- Uncertainties associated with the combination may cause a loss of

employees and may otherwise affect the future business and operations of

Shire and the combined Group.

-- Baxalta only operated as an independent company from July 1, 2015 until

the consummation of its merger with Shire on June 3, 2016, and Baxalta's

historical financial information is not necessarily representative of the

results that Baxalta would have achieved as a separate, publicly traded

company, and may not be a reliable indicator of future results of

Baxalta. Moreover, any pro forma financial information published by

the Group is not necessarily representative of the results that the Group

would have achieved, and may not be a reliable indicator of

future results.

-- Baxter may not satisfy its obligations under various transaction

agreements that have been executed as part of the separation or Shire may

fail to have necessary systems and services in place when certain of the

transaction agreements expire.

-- The acquisition of Baxalta could result in significant liability to the

Group if the combination causes the spin-off of Baxalta from Baxter or a

Later Distribution to be taxable.

-- In connection with the merger with Baxalta, the separation and the Later

Distributions could result in significant liability to the Group due to

Baxalta's spin-off from Baxter.

-- Certain Baxalta agreements may contain change of control provisions that

may have been triggered by the merger that, if acted upon or not waived,

could cause the Group to lose the benefit of such agreement and incur

liabilities or replacement costs, which could have a material adverse

effect on the Group.

-- New regulations issued by the U.S. Department of Treasury may impact

the Group following the merger with Baxalta.

Directors' responsibility statement

The Directors confirm that, to the best of their knowledge, the

condensed consolidated set of financial statements has been prepared in

accordance with U.S. GAAP and that the Half-yearly Report herein

includes a fair review of the information required by DTR 4.2.7R and DTR

4.2.8R.

The Directors of Shire plc are listed in Shire's Annual Report and

Accounts for the year ended December 31, 2016.

Details of all current Directors are available on Shire's website at

www.shire.com

Approved by the Board of Directors and signed on its behalf by:

Flemming Ornskov, M.D., M.P.H.

Chief Executive Officer

August 3, 2017

Jeffrey Poulton

Chief Financial Officer

August 3, 2017

SHIRE PLC

CONSOLIDATED BALANCE SHEETS

(Unaudited, in millions, except par value of shares)

June 30, 2017 December 31, 2016

ASSETS

Current assets:

Cash and cash equivalents $ 263.7 $ 528.8

Restricted cash 34.2 25.6

Accounts receivable, net 2,755.2 2,616.5

Inventories 3,325.3 3,562.3

Prepaid expenses and other current assets 778.5 806.3

Total current assets 7,156.9 7,539.5

Investments 197.0 191.6

Property, plant and equipment ("PP&E"), net 6,554.5 6,469.6

Goodwill 19,482.1 17,888.2

Intangible assets, net 33,434.3 34,697.5

Deferred tax asset 132.2 96.7

Other non-current assets 233.9 152.3

Total assets $ 67,190.9 $ 67,035.4

LIABILITIES AND EQUITY

Current liabilities:

Accounts payable and accrued expenses $ 3,842.0 $ 4,312.4

Short term borrowings and capital leases 3,204.9 3,068.0

Other current liabilities 389.6 362.9

Total current liabilities 7,436.5 7,743.3

Long term borrowings and capital leases 18,355.1 19,899.8

Deferred tax liability 7,788.0 8,322.7

Other non-current liabilities 2,346.2 2,121.6

Total liabilities 35,925.8 38,087.4

Commitments and contingencies

Equity:

Common stock of 5p par value; 1,500 shares authorized;

and 915.3 shares issued and outstanding (2016: 1,500

shares authorized; and 912.2 shares issued and outstanding) 81.5 81.3

Additional paid-in capital 24,951.2 24,740.9

Treasury stock: 8.4 shares (2016: 9.1 shares) (283.0) (301.9 )

Accumulated other comprehensive income/(loss) 200.1 (1,497.6 )

Retained earnings 6,315.3 5,925.3

Total equity 31,265.1 28,948.0

Total liabilities and equity $ 67,190.9 $ 67,035.4

The accompanying notes are an integral part of these Unaudited

Consolidated Financial Statements.

SHIRE PLC

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, in millions, except per share amounts)

Three months ended June

30, Six months ended June 30,

2017 2016 2017 2016

Revenues:

Product sales $3,591.8 $2,322.1 $7,004.1 $3,949.4

Royalties & other revenues 154.0 107.0 314.0 189.0

Total revenues 3,745.8 2,429.1 7,318.1 4,138.4

Costs and expenses:

Cost of sales 1,108.9 778.1 2,435.9 1,026.7

Research and development 542.4 294.8 921.7 511.9

Selling, general and administrative 899.1 675.3 1,788.0 1,150.2

Amortization of acquired intangible assets 434.1 213.0 798.1 347.6

Integration and acquisition costs 343.7 363.0 459.7 454.1

Reorganization costs 13.6 11.0 19.1 14.3

Loss/(gain) on sale of product rights 4.8 (2.3) (0.7) (6.5)

Total operating expenses 3,346.6 2,332.9 6,421.8 3,498.3

Operating income from continuing operations 399.2 96.2 896.3 640.1

Interest income 1.1 1.6 4.2 2.6

Interest expense (141.3) (87.2) (283.6) (131.9)

Other income/(expense), net 2.5 6.0 7.0 (2.5)

Total other expense, net (137.7) (79.6) (272.4) (131.8)

Income from continuing operations before income taxes

and equity in earnings/(losses) of equity method investees 261.5 16.6 623.9 508.3

Income taxes (24.3) 70.9 (31.1) (11.2)

Equity in earnings/(losses) of equity method investees,

net of taxes 4.3 (0.9) 3.5 (1.0)

Income from continuing operations, net of taxes 241.5 86.6 596.3 496.1

(Loss)/gain from discontinued operations, net of taxes (1.2) (248.7) 19.0 (239.2)

Net income/(loss) $ 240.3 $ (162.1) $ 615.3 $ 256.9

The accompanying notes are an integral part of these Unaudited

Consolidated Financial Statements.

SHIRE PLC

CONSOLIDATED STATEMENTS OF OPERATIONS (continued)

(Unaudited, in millions, except per share amounts)

Three months ended June Six months ended June

30, 30,

2017 2016 2017 2016

Earnings/(loss)

per Ordinary

Share - basic

Earnings from

continuing

operations $ 0.27 $ 0.12 $ 0.66 $ 0.78

(Loss)/gain from

discontinued

operations - (0.36) 0.02 (0.38)

Earnings/(loss)

per Ordinary

Share - basic $ 0.27 $ (0.24) $ 0.68 $ 0.40

Earnings/(loss)

per Ordinary

Share - diluted

Earnings from

continuing

operations $ 0.26 $ 0.12 $ 0.65 $ 0.77

(Loss)/earnings

from

discontinued

operations - (0.36) 0.02 (0.37)

Earnings/(loss)

per Ordinary

Share -

diluted $ 0.26 $ (0.24) $ 0.67 $ 0.40

Weighted average

number of

shares:

Basic 906.4 682.8 905.3 637.3

Diluted 912.7 682.8 912.3 640.1

The accompanying notes are an integral part of these Unaudited

Consolidated Financial Statements.

SHIRE PLC

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited, in millions)

Three months ended Six months ended June

June 30, 30,

2017 2016 2017 2016

Net income/(loss) $ 240.3 $(162.1) $ 615.3 $256.9

Other comprehensive income/(loss):

Foreign currency translation adjustments 1,431.0 (220.2) 1,696.5 (195.5)

Pension and other employee benefits (net of tax expense

of $1.3 and $0.9 for the three and six months ended

June 30, 2017 and $nil for both the three and six

months ended June 30, 2016) 3.2 - 10.6 -

Unrealized loss on available-for-sale securities (net

of tax benefit of $0.5 and tax expense of $1.7 for

the three and six months ended June 30, 2017 and tax

benefit of $1.4 for both the three and six months

ended June 30, 2016) (5.6) (4.4) (3.5) (4.7)

Hedging activities (net of tax benefit of $0.5 and

$3.2 for the three and six months ended June 30, 2017

and $1.6 for both the three and six months ended June

30, 2016) (1.4) (1.8) (5.9) (1.8)

Comprehensive income/(loss) $1,667.5 $(388.5) $2,313.0 $ 54.9

The components of Accumulated other comprehensive income/(loss) as of

June 30, 2017 and December 31, 2016 are as follows:

June

30, December 31,

2017 2016

Foreign currency translation adjustments $191.1 $(1,505.4)

Pension and other employee benefits, net of taxes 5.4 (5.2)

Unrealized holding gain on available-for-sale securities,

net of taxes 3.1 6.6

Hedging activities, net of taxes 0.5 6.4

Accumulated other comprehensive income/(loss) $200.1 $(1,497.6)

The accompanying notes are an integral part of these Unaudited

Consolidated Financial Statements.

SHIRE PLC

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

(Unaudited, in millions)

Common

stock Accumulated

number Additional other

of Common paid-in Treasury comprehensive Retained Total

shares stock capital stock income earnings equity

As of January 1, 2017 912.2 $ 81.3 $ 24,740.9 $(301.9) $ (1,497.6 )$5,925.3 $ 28,948.0

Net income - - - - - 615.3 615.3

Other comprehensive income net of tax - - - - 1,697.7 - 1,697.7

Shares issued under employee benefit plans and other 3.1 0.2 93.2 - - - 93.4

Cumulative-effect adjustment from adoption of ASU

2016-09 - - 10.7 - - 28.3 39.0

Share-based compensation - - 106.4 - - - 106.4

Shares released by employee benefit trust to satisfy

exercise of stock options - - - 18.9 - (18.9 ) -

Dividends - - - - - (234.7 ) (234.7)

As of June 30, 2017 915.3 $ 81.5 $ 24,951.2 $(283.0) $ 200.1 $6,315.3 $ 31,265.1

Dividends per share

During the six months ended June 30, 2017, Shire plc declared and paid

dividends of $0.257 U.S. per ordinary share (equivalent to $0.771 U.S.

per ADS) totaling $234.7 million.

The accompanying notes are an integral part of these Unaudited

Consolidated Financial Statements.

SHIRE PLC

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, in millions)

Six months ended June 30,

2017 2016

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income $ 615.3 $ 256.9

Adjustments to reconcile net income to net cash provided

by operating activities:

Depreciation and amortization 1,041.7 429.8

Share based compensation 106.4 194.8

Amortization of deferred financing fees 6.8 50.1

Expense related to the unwind of inventory fair value

adjustments 625.4 293.5

Change in deferred taxes (293.3) (329.2)

Change in fair value of contingent consideration 147.7 (45.0)

Impairment of PP&E and intangible assets 53.6 8.9

Other, net 14.8 (17.6)

Changes in operating assets and liabilities:

Increase in accounts receivable (181.5) (181.0)

Increase in sales deduction accrual 57.1 66.4

Increase in inventory (171.6) (116.4)

Decrease in prepayments and other assets 104.6 26.5

(Decrease)/increase in accounts payable and other

liabilities (445.1) 342.7

Net cash provided by operating activities 1,681.9 980.4

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchases of PP&E and long term investments (391.1) (179.1)

Purchases of businesses, net of cash acquired - (17,476.2)

Proceeds from sale of investments 40.6 -

Movements in restricted cash (8.6) 67.2

Other, net 3.2 3.3

Net cash used in investing activities (355.9) (17,584.8)

The accompanying notes are an integral part of these Unaudited

Consolidated Financial Statements.

SHIRE PLC

CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)

(Unaudited, in millions)

Six months ended June 30,

2017 2016

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from revolving line of credit, long term

and short term borrowings 2,111.9 18,895.0

Repayment of revolving line of credit, long term and

short term borrowings (3,527.9) (1,500.3)

Payment of dividend (234.7) (130.2)

Debt issuance costs - (112.3)

Proceeds from exercise of options 79.5 0.1

Other, net (24.0) 11.9

Net cash (used in)/provided by financing activities (1,595.2) 17,164.2

Effect of foreign exchange rate changes on cash and

cash equivalents 4.1 (1.9)

Net (decrease)/increase in cash and cash equivalents (265.1) 557.9

Cash and cash equivalents at beginning of period 528.8 135.5

Cash and cash equivalents at end of period $ 263.7 $ 693.4

Supplemental information:

Six months ended June 30,

2017 2016

Interest paid $ 267.0 $ 111.4

Income taxes paid, net $ 176.0 $ 253.7

For stock issued as purchase consideration for the acquisition of

Baxalta related to non-cash investing activities, refer to Note 2,

Business Combinations, to these Unaudited Consolidated Financial

Statements.

The accompanying notes are an integral part of these Unaudited

Consolidated Financial Statements.

SHIRE PLC

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

1. Summary of Significant Accounting Policies

Basis of Presentation

These interim financial statements of Shire plc and its subsidiaries

(collectively "Shire" or the "Group") are unaudited. They have been

prepared in accordance with generally accepted accounting principles in

the United States of America ("U.S. GAAP").

The Consolidated Balance Sheet as of December 31, 2016 was derived from

the Audited Consolidated Financial Statements as of that date.

These interim Unaudited Consolidated Financial Statements should be read

in conjunction with the Consolidated Financial Statements and

accompanying notes included in the Group's Annual Report and Accounts

for the year ended December 31, 2016, as filed with the SEC on February

22, 2017.

Certain information and footnote disclosures normally included in

financial statements prepared in accordance with U.S. GAAP have been

condensed or omitted from these interim financial statements. However,

these interim financial statements include all adjustments, consisting

of normal recurring adjustments, which are, in the opinion of management,

necessary to fairly state the results of the interim period and the

Group believes that the disclosures are adequate to make the information

presented not misleading. Interim results are not necessarily indicative

of results to be expected for the full year.

On June 3, 2016, the Group completed its acquisition of Baxalta for

$32.4 billion, representing the fair value of purchase consideration.

The Group's Unaudited Consolidated Financial Statements include the

results of Baxalta from the date of acquisition. For further details

regarding the acquisition, refer to Note 2, Business Combinations, of

these Unaudited Consolidated Financial Statements.

Use of Estimates

The preparation of Financial Statements, in conformity with U.S. GAAP

and SEC regulations, requires management to make estimates, judgments

and assumptions that affect the reported and disclosed amounts of assets,

liabilities and equity at the date of the Unaudited Consolidated

Financial Statements and reported amounts of revenues and expenses

during the period. On an on-going basis, the Group evaluates its

estimates, judgments and methodologies. Estimates are based on

historical experience, current conditions and on various other

assumptions that are reasonable under the circumstances, the results of

which form the basis for making judgments about the carrying values of

assets, liabilities and equity and the amounts of revenues and expenses.

Actual results may differ from these estimates under different

assumptions or conditions.

New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the

Financial Accounting Standards Board ("FASB") or other standard setting

bodies that the Group adopts as of the specified effective date. Unless

otherwise discussed below, the Group does not believe that the impact of

recently issued standards that are not yet effective will have a

material impact on the Group's financial position or results of

operations upon adoption.

Adopted during the current period

Inventory

In July 2015, the FASB issued new guidance which requires an entity to

measure inventory at the lower of cost and net realizable value. Net

realizable value is defined as the estimated selling prices in the

ordinary course of business, less reasonably predictable costs of

completion, disposal and transportation. The Group adopted this standard

as of January 1, 2017, which did not impact the Group's financial

position or results of operations.

Share-Based Payment Accounting

In March 2016, the FASB issued Accounting Standards Update ("ASU") No.

2016-09, Compensation - Stock Compensation (Topic 718): Improvements to

Employee Share-Based Payment Accounting. The new standard requires

recognition of the income tax effects of vested or settled awards in the

income statement and involves several other aspects of the accounting

for share-based payment transactions, including the income tax

consequences, classification of awards as either equity or liabilities

and classification on the statement of cash flows and allows a one-time

accounting policy election to account for forfeitures as they occur. The

new standard was effective January 1, 2017.

The Group adopted ASU 2016-09 in the first quarter of 2017. Before

adoption, excess tax benefits or deficiencies from the Group's equity

awards were recorded as Additional paid-in capital in its Consolidated

Balance Sheets. Upon adoption, the Group recorded any excess tax

benefits or deficiencies from its equity awards in its Consolidated

Statements of Operations in the reporting periods in which vesting or

settlement occurs.

Amendments related to accounting for excess tax benefits have been

adopted prospectively, resulting in recognition of excess tax benefits

against Income taxes rather than Additional paid-in capital of $11.5

million for the six months ended June 30, 2017.

As a result of the adoption, the Group recorded an adjustment to

Retained earnings of $39.0 million to recognize net operating loss

carryforwards attributable to excess tax benefits on stock compensation

that had not been previously recognized to Additional paid-in capital.

Excess tax benefits for share-based payments are now included in Net

cash provided by operating activities rather than Net cash provided by

financing activities. The changes have been applied prospectively in

accordance with the ASU and prior periods have not been adjusted.

Upon adoption of ASU 2016-09, the Group elected to account for

forfeitures in relation to service conditions as they occur. The change

was applied on a modified retrospective basis with a cumulative effect

adjustment to Retained earnings of $10.7 million as of January 1, 2017.

Definition of a Business

In January 2017, the FASB issued ASU No. 2017-01, Business Combinations

(Topic 805): Clarifying the Definition of a Business. This new standard

clarifies the definition of a business and provides guidance to

determine when an integrated set of assets and activities is not a

business. The Group adopted this standard prospectively on January 1,

2017.

To be adopted in future periods

Simplifying the Test for Goodwill Impairment

In January 2017, the FASB issued ASU No. 2017-04, Intangibles - Goodwill

and Other (Topic 350): Simplifying the Test of Goodwill Impairment. This

new standard simplifies how an entity is required to test goodwill for

impairment by eliminating Step 2 from the goodwill impairment test. Step

2 measures a goodwill impairment loss by comparing the implied fair

value of a reporting unit's goodwill with the carrying amount of that

goodwill. This standard will be effective for the Group as of January 1,

2020, with early adoption permitted for annual goodwill impairment tests

performed after January 1, 2017. The Group does not expect the adoption

of this standard to have a material impact on its financial position and

results of operations.

Revenue from Contracts with Customers

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts

with Customers (Topic 606), which supersedes all existing revenue

recognition requirements, including most industry-specific guidance. The

new standard requires a Group to recognize revenue when it transfers

goods or services to customers in an amount that reflects the

consideration that the Group expects to receive for those goods or

services. The new standard also requires additional qualitative and

quantitative disclosures.

In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts

with Customers (Topic 606): Deferral of the Effective Date, which

delayed the effective date of the new standard from January 1, 2017 to

January 1, 2018. The FASB also agreed to allow entities to choose to

adopt the standard as of the original effective date.

The FASB has subsequently issued five additional ASUs amending the

guidance in Topic 606, each with the same effective date and transition

date of January 1, 2018. This amended guidance has been considered in

the Group's overall assessment of the new standard.

Shire will adopt this standard on the effective date of January 1, 2018.

The Group is currently evaluating the method of adoption and the

potential impact on its financial position and results of operations of

adopting this guidance. The Group has identified two primary revenue

streams from contracts with customers as part of its initial assessment:

1) product sales and 2) licensing arrangements. Shire is in the process

of evaluating these contracts and is not yet able to estimate the

anticipated impact to the Group's financial statements from the

application of the new standard.

Financial Instrument Accounting

In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments

- Overall (Subtopic 825-10): Recognition and Measurement of Financial

Assets and Financial Liabilities. The new standard amends certain

aspects of accounting and disclosure requirements of financial

instruments, including the requirement that equity investments with

readily determinable fair values be measured at fair value with changes

in fair value recognized in the results of operations. This standard

will be effective for the Group as of January 1, 2018. The Group is

currently evaluating the method of adoption and the potential impact on

its financial position and results of operations of adopting this

guidance.

Leases

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842).

The new accounting guidance will require the recognition of all lease

assets and lease liabilities by lessees and sets forth new disclosure

requirements for those lease assets and liabilities. The standard

requires lessees to recognize right-of-use assets and lease liabilities

on the balance sheet using a modified retrospective approach at the

beginning of the earliest comparative period in the financial

statements. This standard will be effective for the Group as of January

1, 2019. Early adoption is permitted. The Group is currently evaluating

the potential impact on its financial position and results of operations

of adopting this guidance.

Statement of Cash Flows

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows

(Topic 230): Classification of Certain Cash Receipts and Cash Payments.

The new standard clarifies certain aspects of the statement of cash

flows, and aims to reduce diversity in practice regarding how certain

transactions are classified in the statement of cash flows. This

standard will be effective for the Group as of January 1, 2018. Early

adoption is permitted. The adoption of this guidance is not expected to

have a significant impact on the Group's Consolidated Statement of Cash

Flows.

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows

(Topic 230): Restricted Cash. The new guidance is intended to reduce

diversity in the presentation of restricted cash and restricted cash

equivalents in the statement. The guidance requires that restricted

cash and restricted cash equivalents be included as components of total

cash and cash equivalents as presented on the statement of cash flows.

This standard will be effective for the Group as of January 1, 2018. The

adoption of this guidance is not expected to have a significant impact

on the Group's Consolidated Statements of Cash Flows.

Income Taxes

In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic

740): Intra-Entity Transfers Other than Inventory. This standard removes

the current exception in U.S. GAAP prohibiting entities from recognizing

current and deferred income tax expenses or benefits related to transfer

of assets, other than inventory, within the consolidated entity. The

current exception to defer the recognition of any tax impact on the

transfer of inventory within the consolidated entity until it is sold to

a third party remains unaffected. This standard will be effective for

the Group as of January 1, 2018, with the early adoption permitted. The

Group is currently evaluating the method of adoption and the potential

impact on its financial position and results of operations of adopting

this guidance.

Retirement Benefits Income Statement Presentation

In March 2017, the FASB issued ASU 2017-07 Compensation - Retirement

Benefits (Topic 715): Improving the Presentation of Net Periodic Pension

Cost and Net Periodic Postretirement Benefit Cost. The standard amends

the income statement presentation of the components of net periodic

benefit cost for defined benefit pension and other postretirement plans.

The standard requires entities to (1) disaggregate the

current-service-cost component from the other components of net benefit

cost (the "other components") and present it with other current

compensation costs for related employees in the income statement and (2)

present the other components elsewhere in the income statement and

outside of income from operations if such a subtotal is presented. The

standard also requires entities to disclose the income statement lines

that contain the other components if they are not presented on

appropriately described separate lines. This standard will be effective

for the Group as of January 1, 2018. The Group does not expect the

adoption of this standard to have a material impact on its financial

position and results of operations.

Share-Based Payment Accounting

In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock

Compensation (Topic 718): Scope Modification Accounting. The new

standard clarifies when changes to the terms or conditions of a

share-based payment award must be accounted for as modifications. This

standard will be effective for the Group as of January 1, 2018. Early

adoption is permitted. The adoption of this guidance is not expected to

have a significant impact on the Group's financial position and results

of operations.

Going concern

The Directors have a reasonable expectation that the Group has adequate

resources to continue in operational existence for the foreseeable

future. Accordingly, the Directors consider it appropriate to adopt the

going concern basis of accounting in preparing the Half-yearly Report.

2. Business Combinations

Acquisition of Baxalta

On June 3, 2016, Shire acquired all of the outstanding common stock of

Baxalta for $18.00 per share in cash and 0.1482 Shire American

Depository Shares ("ADSs") per Baxalta share, or if a former Baxalta

shareholder properly elected, 0.4446 Shire ordinary shares per Baxalta

share.

Baxalta was a global biopharmaceutical company that focused on

developing, manufacturing and commercializing therapies for orphan

diseases and underserved conditions in hematology, immunology and

oncology.

The purchase price consideration for the acquisition of Baxalta was

finalized in the second quarter of 2017. The fair value of the purchase

price consideration consisted of the following:

(In millions) Fair value

Cash paid to shareholders $ 12,366.7

Fair value of stock issued to shareholders 19,353.2

Fair value of partially vested stock options and RSUs

assumed 508.8

Contingent consideration payable 165.0

Total purchase price consideration $ 32,393.7

The acquisition of Baxalta was accounted for as a business combination

using the acquisition method of accounting. Shire issued 305.2 million

shares to former Baxalta shareholders at the date of the acquisition.

For a more detailed description of the fair value of the partially

vested stock options and RSUs assumed, refer to Note 27, Share-based

Compensation Plans, of the Group's Annual Report and Accounts for the

year ended December 31, 2016.

The assets acquired and the liabilities assumed from Baxalta have been

recorded at their fair value as of June 3, 2016, the date of

acquisition. The Group's Unaudited Consolidated Financial Statements

included the results of Baxalta from the date of acquisition.

500 /libs/foundation/components/parsys/parsys.jsp

/libs/foundation/components/parsys/parsys.jsp

Cannot serve request to /content/fox-business/features/2017/08/04/shire-plc-shire-plc-half-yearly-report-19.html on this server


ApacheSling/2.3 (jetty/8.1.14.v20131031, Java HotSpot(TM) 64-Bit Server VM 1.7.0_80, Linux 2.6.32-431.el6.x86_64 amd64)